Stock Analiz

GSK plc (GSK) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

GSK’s revenue went from $34.3B in fiscal 2016 to $44.0B in fiscal 2025, growth of about 2.8% a year.

Net income in fiscal 2025 was $7.7B, a net margin of 17.5%; the best year in this period was 2022 with $18.0B.

Over the twelve months to September 30, 2026, revenue was $44.3B and net income $5.7B.

Free cash flow was $8.6B in fiscal 2025 and positive in 10 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $34.3B162017: $40.8B172018: $39.5B182019: $44.6B192020: $33.2B202021: $33.3B212022: $35.3B222023: $38.6B232024: $39.3B242025: $44.0B25$44.0B
Net income
2016: $1.1B162017: $2.1B172018: $4.6B182019: $6.1B192020: $7.8B202021: $5.9B212022: $18.0B222023: $6.3B232024: $3.2B242025: $7.7B25$7.7B
Free cash flow
2016: $6.1B162017: $7.3B172018: $9.1B182019: $8.9B192020: $10.2B202021: $9.4B212022: $7.5B222023: $6.9B232024: $6.5B242025: $8.6B25$8.6B
EPS (diluted)
2016: $0.56162017: $1.02172018: $2.29182019: $3.03192020: $3.88202021: $2.92212022: $8.89222023: $3.10232024: $1.59242025: $3.8125$3.81

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$44.3B$44.0B$39.3B$38.6B$35.3B$33.3B$33.2B$44.6B$39.5B$40.8B$34.3B
Gross profit—$31.8B$28.0B$27.7B$23.8B$22.3B$22.4B$28.9B$26.3B$26.8B$22.9B
Operating income—$10.7B$5.0B$8.6B$7.7B$5.9B$8.2B$9.2B$7.0B$5.5B$3.2B
Net income$5.7B$7.7B$3.2B$6.3B$18.0B$5.9B$7.8B$6.1B$4.6B$2.1B$1.1B
EPS (diluted)$2.82$3.81$1.59$3.10$8.89$2.92$3.88$3.03$2.29$1.02$0.56
R&D———————————
Revenue growth—+11.9%+1.9%+9.3%+5.9%+0.1%−25.4%+13.0%−3.3%+18.8%−3.2%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$11.8B$10.4B$8.2B$8.6B$8.9B$10.7B$11.5B$10.6B$10.8B$9.4B$8.0B
Capital spending-$3.5B-$1.8B-$1.8B-$1.7B-$1.4B-$1.3B-$1.3B-$1.7B-$1.7B-$2.1B-$1.9B
Free cash flow$8.3B$8.6B$6.5B$6.9B$7.5B$9.4B$10.2B$8.9B$9.1B$7.3B$6.1B
Dividends paid$3.6B$3.5B$3.1B$2.9B$4.2B$5.4B$5.4B$5.2B$5.0B$5.3B$6.0B
Buybacks—$1.9B$0$0———————
Stock-based pay—$504M$431M$390M$416M$462M$460M$482M$461M$450M$393M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$4.6B$4.8B$3.7B$4.5B$5.8B$8.6B$6.2B$5.0B$5.2B$6.0B
Debt—$23.9B$21.3B$22.9B$25.2B$32.6B$37.1B$40.3B$33.4B$23.1B$23.1B
Equity—$22.1B$17.1B$17.0B$12.7B$20.3B$19.9B$15.1B$4.8B-$92M$1.4B
Total assets—$82.3B$74.5B$75.0B$72.3B$106.6B$109.8B$105.2B$74.3B$76.2B$72.7B
Shares (diluted)2.04B2.02B2.02B2.02B2.02B2.02B2.02B2.02B2.02B2.02B2.02B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—72.4%71.2%71.8%67.4%67.0%67.4%64.8%66.8%65.7%66.7%
Operating margin—24.3%12.8%22.2%21.9%17.6%24.6%20.6%17.8%13.5%9.3%
Net margin13.0%17.5%8.2%16.2%51.0%17.8%23.6%13.8%11.8%5.1%3.3%
FCF margin18.7%19.6%16.4%18.0%21.3%28.3%30.6%20.0%23.0%17.8%17.8%
ROIC—19.8%11.1%18.8%17.8%10.8%14.1%14.1%15.5%14.8%7.1%
ROE—34.9%18.8%36.9%141.1%29.1%39.4%40.7%95.8%-2252.9%81.1%

Frequently asked questions

What is GSK’s annual revenue?

$44.0B in fiscal 2025 and $44.3B over the twelve months to September 30, 2026.

How much profit does GSK make?

Net income was $7.7B in fiscal 2025 (net margin 17.5%).

Is GSK’s revenue growing?

Yes: revenue rose 11.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.